KROS — Keros Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1664710 ·
Last close
$10.78
Market Cap
$213.74M
52W High
$12.19
52W Low
$9.69
ADV30
202,216
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -30,937,000 | -28,710,000 | 287,600,000 | 257,606,000 | 25,280,000 |
| Mar 2026 | 367,000 | — | -25,877,000 | -23,708,000 | 312,293,000 | 281,497,000 | 26,663,000 |
| Dec 2025 | 385,000 | — | -29,270,000 | -23,461,000 | 338,021,000 | 287,415,000 | 34,889,000 |
| Sep 2025 | 14,262,000 | — | -15,384,000 | -7,280,000 | 742,783,000 | 693,472,000 | 39,203,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,993,000
Investing CF
$-494,000
Financing CF
$-384,122,000
CapEx
$-494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-534,183,000
Inventory
—
Receivables
$2,757,000
ST Investments
—
EBIT TTM
$-101,468,000
Pretax Income TTM
$-86,097,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,014,000
EBITDA
$-96,868,000
Free Cash Flow
$-27,174,500
Enterprise Value
$-23,188,116
Total Cash
$257,606,000
Total Debt
$15,724,000
Shares Out
19,827,188
Trailing EPS
$-3.22
Book Value
$13.23
ROE
-17.2%
ROA
-11.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 244,061,000 | 67,569,000 | 87,014,000 | 338,021,000 | 34,889,000 | — | 107,505,000 |
| Dec 2024 | 3,550,000 | -209,595,000 | -187,353,000 | 615,886,000 | 44,333,000 | — | -160,869,000 |
| Dec 2023 | 151,000 | -167,541,000 | -152,992,000 | 370,025,000 | 37,812,000 | — | -124,508,000 |
| Dec 2022 | 0 | -107,709,000 | -104,679,000 | 306,781,000 | 29,358,000 | — | -70,062,000 |
TTM Snapshot
Revenues TTM
$396,000
NetIncome TTM
$-136,202,000
OpCashFlow TTM
$0
Assets (Latest)
$615,886,000
Forward EPS
$-6.62
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $10.78 · call volume: 20 · put volume: 13
Expected Move to 2026-09-18:
±$1.78
(16.51%) —
implied range
$9.00 –
$12.56
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $213.53M | $12.45 | — |
| ORGO | Organogenesis Holdings Inc. | $214.89M | $1.67 | — |
| ANTX | AN2 Therapeutics, Inc. | $212.46M | $5.63 | — |
| NGEN | NERVGEN PHARMA CORP. | $215.05M | $2.00 | — |
| SIGA | SIGA TECHNOLOGIES INC | $211.24M | $2.94 | — |
News headlines (Yahoo Finance, 1h cache)
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
2026-08-14 23:37 · Yahoo
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
2026-07-30 20:01 · Yahoo
Keros Therapeutics Appoints Anne Prener to its Board of Directors
2026-06-25 20:01 · Yahoo
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-01 20:01 · Yahoo
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
2026-05-17 13:36 · Yahoo
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
2026-04-03 15:30 · Yahoo
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
2026-08-24 16:53 · Yahoo
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
2026-08-24 16:51 · Yahoo
Keros Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-03 20:01 · Yahoo
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.